Although data shows that severe #COVID19 is rare in children, widespread vaccination is a critical tool to help stop transmission. That’s why I’m excited we have begun dosing participants aged 5 to 11 in a global Phase 2/3 study of the Pfizer-BioNTech #COVID19 vaccine.

— Albert Bourla (@AlbertBourla) June 8, 2021

>

https://twitter.com/AlbertBourla/status/1402240820120592393

- AlbertBourla